PE20220645A1 - Formas polimorficas de (r)-4- (1-((3- (difluorometil)-1-metil-1h- pirazol-4-il)sulfonil) -1- fluoroetil)-n-(isoxazol-3-il)piperidina -1- carboxamida - Google Patents
Formas polimorficas de (r)-4- (1-((3- (difluorometil)-1-metil-1h- pirazol-4-il)sulfonil) -1- fluoroetil)-n-(isoxazol-3-il)piperidina -1- carboxamidaInfo
- Publication number
- PE20220645A1 PE20220645A1 PE2022000049A PE2022000049A PE20220645A1 PE 20220645 A1 PE20220645 A1 PE 20220645A1 PE 2022000049 A PE2022000049 A PE 2022000049A PE 2022000049 A PE2022000049 A PE 2022000049A PE 20220645 A1 PE20220645 A1 PE 20220645A1
- Authority
- PE
- Peru
- Prior art keywords
- fluoroethyl
- pyrazol
- carboxamide
- piperidine
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion proporciona nuevos polimorfos de (R)-4-(1-((3- (difluorometil)-1-metil-1H-pirazol-4-il)sulfonil)-1-fluoroetil)-N-(isoxazol-3 -il) piperidina-1- carboxamida (I-491) que son utiles para el tratamiento de trastornos cardiacos que incluyen disfuncion sistolica, miocardiopatia dilatada (DCM), insuficiencia cardiaca con fraccion de eyeccion reservada (HFrEF) y afecciones asociadas con el lado izquierdo y/o disfuncion sistolica del ventriculo derecho o reserva sistolica. Se describe la sintesis y caracterizacion de los polimorfos, asi como los metodos para tratar la disfuncion sistolica, DCM, HFrEF y otras formas de enfermedad cardiaca.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962874855P | 2019-07-16 | 2019-07-16 | |
PCT/US2020/042028 WO2021011586A1 (en) | 2019-07-16 | 2020-07-15 | Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20220645A1 true PE20220645A1 (es) | 2022-04-28 |
Family
ID=71895284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022000049A PE20220645A1 (es) | 2019-07-16 | 2020-07-15 | Formas polimorficas de (r)-4- (1-((3- (difluorometil)-1-metil-1h- pirazol-4-il)sulfonil) -1- fluoroetil)-n-(isoxazol-3-il)piperidina -1- carboxamida |
Country Status (15)
Country | Link |
---|---|
US (2) | US20210053939A1 (es) |
EP (1) | EP3999504A1 (es) |
JP (1) | JP2022540678A (es) |
KR (1) | KR20220035176A (es) |
CN (1) | CN114127061A (es) |
AU (1) | AU2020315605A1 (es) |
BR (1) | BR112022000474A2 (es) |
CA (1) | CA3143965A1 (es) |
CL (1) | CL2022000050A1 (es) |
CO (1) | CO2022000117A2 (es) |
IL (1) | IL289817A (es) |
MX (1) | MX2022000606A (es) |
PE (1) | PE20220645A1 (es) |
TW (1) | TW202116765A (es) |
WO (1) | WO2021011586A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116082326A (zh) * | 2022-12-16 | 2023-05-09 | 药康众拓(江苏)医药科技有限公司北京分公司 | 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途 |
CN117865941B (zh) * | 2024-03-13 | 2024-06-28 | 上海方予健康医药科技有限公司 | 取代哌啶化合物及其制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111393414B (zh) * | 2015-01-22 | 2024-05-07 | 迈奥卡迪亚公司 | 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物 |
-
2020
- 2020-07-15 PE PE2022000049A patent/PE20220645A1/es unknown
- 2020-07-15 CA CA3143965A patent/CA3143965A1/en active Pending
- 2020-07-15 EP EP20750115.6A patent/EP3999504A1/en active Pending
- 2020-07-15 AU AU2020315605A patent/AU2020315605A1/en active Pending
- 2020-07-15 CN CN202080051794.8A patent/CN114127061A/zh active Pending
- 2020-07-15 WO PCT/US2020/042028 patent/WO2021011586A1/en active Application Filing
- 2020-07-15 KR KR1020227004725A patent/KR20220035176A/ko active Search and Examination
- 2020-07-15 MX MX2022000606A patent/MX2022000606A/es unknown
- 2020-07-15 BR BR112022000474A patent/BR112022000474A2/pt unknown
- 2020-07-15 US US16/929,230 patent/US20210053939A1/en not_active Abandoned
- 2020-07-15 TW TW109123966A patent/TW202116765A/zh unknown
- 2020-07-15 JP JP2022502486A patent/JP2022540678A/ja active Pending
-
2022
- 2022-01-10 CL CL2022000050A patent/CL2022000050A1/es unknown
- 2022-01-12 CO CONC2022/0000117A patent/CO2022000117A2/es unknown
- 2022-01-12 IL IL289817A patent/IL289817A/en unknown
- 2022-02-23 US US17/678,569 patent/US20220289709A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN114127061A (zh) | 2022-03-01 |
CO2022000117A2 (es) | 2022-01-17 |
CA3143965A1 (en) | 2021-01-21 |
EP3999504A1 (en) | 2022-05-25 |
AU2020315605A1 (en) | 2022-03-03 |
US20220289709A1 (en) | 2022-09-15 |
IL289817A (en) | 2022-03-01 |
TW202116765A (zh) | 2021-05-01 |
MX2022000606A (es) | 2022-03-11 |
JP2022540678A (ja) | 2022-09-16 |
KR20220035176A (ko) | 2022-03-21 |
WO2021011586A1 (en) | 2021-01-21 |
BR112022000474A2 (pt) | 2022-05-17 |
CL2022000050A1 (es) | 2022-10-14 |
US20210053939A1 (en) | 2021-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2022000172A (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd) | |
CL2022000050A1 (es) | Formas polimórficas de (r)-4- (1-((3- (difluorometil)-1-metil-1h-pirazol-4-il)sulfonil) -1-fluoroetil)-n-(isoxazol-3-il)piperidina -1-carboxamida | |
CL2020000427A1 (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos. | |
DOP2021000070A (es) | Inhibidores de la proteína tirosina fosfatasa | |
MX2022014414A (es) | Compuestos de pirimidinodiona contra estados cardiacos. | |
CO2021015505A2 (es) | Tratamiento de la disfunción sistólica e insuficiencia cardíaca con fracción de eyección reducida con el compuesto (r) -4-(1-((3-(difluorometil) -1-metil-1h-pirazol-4-il) sulfonil) -1-fluoroetil) -n-(isoxazol-3-il) piperidin-1-carboxamida | |
UY37302A (es) | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa | |
UY38160A (es) | Partículas implantables y métodos relacionados | |
NI201200016A (es) | Derivados de piridina y pirazina como moduladores de cinasa de proteína | |
CO2021005540A2 (es) | Compuestos de pirimidinodiona bicíclicos sustituidos con tetrahidropirano (thp) | |
BR112022000494A2 (pt) | Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica | |
WO2016023028A3 (en) | G protein-coupled receptor kinase 2 inhibitors and methods for use of the same | |
UY38925A (es) | Procedimiento para la preparación del ácido 5-bromo-2-(3-cloro-piridin-2-il)-2h-pirazol-3-carboxílico | |
IL277141A (en) | Compounds for the treatment of heart rhythm disturbances and heart failure | |
NZ772098A (en) | 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm) | |
SG11202112499VA (en) | Treatment of heart disease by disruption of the anchoring of pp2a |